StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)

Close on Nov 17, 2026Market cap $529.90MP/E –Yield –

Myriad Genetics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Myriad Genetics's price to sales ratio was 0.7× on Nov 11, 2026, against 0.9× a year earlier. Over the last 5 years it ranged from 0.3× to 3.3×, with a median of 2.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.7×−0.0
2025Dec 31, 20250.7×−0.8
2024Dec 31, 20241.5×−0.6
2023Dec 29, 20232.1×+0.3
2022Dec 30, 20221.8×−1.4
2021Dec 31, 20213.2×+0.9
2020Dec 31, 20202.3×−0.1
2019Dec 31, 20192.4×−0.4
2018Dec 31, 20182.8×−0.3
2017Dec 29, 20173.1×+1.5
2016Dec 30, 20161.5×−2.5
2015Dec 31, 20154.1×+0.7
2014Dec 31, 20143.3×+1.0
2013Dec 31, 20132.4×−1.9
2012Dec 31, 20124.3×+0.1
2011Dec 30, 20114.2×−1.5
2010Dec 31, 20105.7×−2.2
2009Dec 31, 20097.9×–

More Myriad Genetics figures

See a number that looks wrong?